Gilead agrees to buy Kite Pharma, leaping into CAR-T cancer therapy

The CAR-T production line at Kite’s factory in El Segundo, Calif.


nvestors wanted Gilead Sciences to shake things up with a big, transformative acquisition and that’s what the company did Monday, agreeing to buy Kite Pharma and its CAR-T cancer-killing technology for $11.9 billion.

Gilead is paying $180 per share, all in cash, for Kite, or a 29 percent premium over its closing stock price Friday.



Leave a Reply